Skip to main content
SpringerLink
Log in

Importance of Prognostic Factors in Lung Cancer

  • Chapter
  • First Online:
Advances in Radiation Oncology in Lung Cancer

Part of the book series: Medical Radiology ((Med Radiol Radiat Oncol))

  • 332 Accesses

Abstract

Lung cancer is still one of the most common types of cancer worldwide and remained the leading cause of cancer deaths, with an estimated 1.8 million deaths (18%), in 2020 (Sung et al. 2021). Also, lung cancer cases have continuously increased in the last decade with more than 2.2 million (11.4% of all incident cancers) estimated today.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Alexander M, Wolfe R, Ball D, Conron M, Stirling RG, Solomon B, MacManus M, Officer A, Karnam S, Burbury K (2017) Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer. Br J Cancer 117:744

    Google Scholar 

  • Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, Iyer AK (2017) PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561

    Google Scholar 

  • Anraku M, Waddell TK (2006) Surgery for small-cell lung cancer. Semin Thorac Cardiovasc Surg 18:211–216. https://doi.org/10.1053/j.semtcvs.2006.08.006

    Article  Google Scholar 

  • Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M (2017) Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med 377:1919–1929

    Google Scholar 

  • Asmis TR, Ding K, Seymour L, Shepherd FA, Leighl NB, Winton TL, Whitehead M, Spaans JN, Graham BC, Goss GD (2008) Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol 26:54–59

    Google Scholar 

  • Bennett BM, Wells JR, Panter C, Yuan Y, Penrod JR (2017) The humanistic burden of small cell lung cancer (SCLC): a systematic review of health-related quality of life (HRQoL) Literature. Front Pharmacol 8:339. https://doi.org/10.3389/fphar.2017.00339

    Article  Google Scholar 

  • Berghmans T, Dusart M, Paesmans M, Hossein-Foucher C, Buvat I, Castaigne C, Scherpereel A, Mascaux C, Moreau M, Roelandts M (2008) Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. J Thorac Oncol 3:6–12

    Google Scholar 

  • Bremnes RM, Sundstrom S, Aasebø U, Kaasa S, Hatlevoll R, Aamdal S (2003) The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up. Lung Cancer 39:303–313. https://doi.org/10.1016/s0169-5002(02)00508-1

    Article  Google Scholar 

  • Brierley JD, Gospodarowicz MK, Wittekind C (2017) TNM classification of malignant tumours. John Wiley & Sons

    Google Scholar 

  • Buccheri G, Ferrigno D, Barisione E, Noceti P (2004) Prognostic factors in advanced stage non-small cell lung cancer. Minerva Pneumol 43:131–142

    Google Scholar 

  • Buentzel J, Heinz J, Bleckmann A, Bauer C, Roever C, Bohnenberger H, Saha S, Hinterthaner M, Baraki H, Kutschka I (2019) Sarcopenia as prognostic factor in lung cancer patients: a systematic review and meta-analysis. Anticancer Res 39:4603–4612

    Google Scholar 

  • Cerny T, Anderson H, Bramwell V, Thatcher N, Blair V (1987) Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer 39:146–149. https://doi.org/10.1002/ijc.2910390204

    Article  Google Scholar 

  • Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L (2015) Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol 16:630–637

    Google Scholar 

  • Chardin D, Paquet M, Schiappa R, Darcourt J, Bailleux C, Poudenx M, Sciazza A, Ilie M, Benzaquen J, Martin N (2020) Baseline metabolic tumor volume as a strong predictive and prognostic biomarker in patients with non-small cell lung cancer treated with PD1 inhibitors: a prospective study. J Immunother Cancer 8(2):e000645

    Google Scholar 

  • Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383

    Google Scholar 

  • Chen T, Zhou F, Jiang W, Mao R, Zheng H, Qin L, Chen C (2019) Age at diagnosis is a heterogeneous factor for non-small cell lung cancer patients. J Thorac Dis 11:2251

    Google Scholar 

  • Choi YS, Shim YM, Kim J, Kim K (2002) Recurrence-free survival and prognostic factors in resected pN2 non-small cell lung cancer. Eur J Cardiothorac Surg 22:695–700

    Google Scholar 

  • Colinet B, Jacot W, Bertrand D, Lacombe S, Bozonnat M, Daures J, Pujol J (2005) A new simplified comorbidity score as a prognostic factor in non-small-cell lung cancer patients: description and comparison with the Charlson’s index. Br J Cancer 93:1098–1105

    Google Scholar 

  • Collins J, Noble S, Chester J, Coles B, Byrne A (2014) The assessment and impact of sarcopenia in lung cancer: a systematic literature review. BMJ Open 4

    Google Scholar 

  • Couñago F, Luna J, Guerrero LL, Vaquero B, Guillén-Sacoto MC, González-Merino T, Taboada B, Díaz V, Rubio-Viqueira B, Díaz-Gavela AA, Marcos FJ, Del Cerro E (2019) Management of oligometastatic non-small cell lung cancer patients: current controversies and future directions. World J Clin Oncol 10:318–339. https://doi.org/10.5306/wjco.v10.i10.318

    Article  Google Scholar 

  • Dall’Olio FG, Maggio I, Massucci M, Mollica V, Fragomeno B, Ardizzoni A (2020) ECOG performance status≥ 2 as a prognostic factor in patients with advanced non small cell lung cancer treated with immune checkpoint inhibitors—a systematic review and meta-analysis of real world data. Lung Cancer 145:95–104

    Google Scholar 

  • Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK (2019) Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am Soc Clin Oncol Educ Book 39:165–174

    Google Scholar 

  • Detterbeck FC, Marom EM, Arenberg DA, Franklin WA, Nicholson AG, Travis WD, Girard N, Mazzone PJ, Donington JS, Tanoue LT, Rusch VW, Asamura H, Rami-Porta R (2016) The IASLC lung cancer staging project: background data and proposals for the application of TNM staging rules to lung cancer presenting as multiple nodules with ground glass or lepidic features or a pneumonic type of involvement in the forthcoming eighth edition of the TNM classification. J Thorac Oncol 11:666–680. https://doi.org/10.1016/j.jtho.2015.12.113

    Article  Google Scholar 

  • Faivre-Finn C, Snee M, Ashcroft L, Appel W, Barlesi F, Bhatnagar A, Bezjak A, Cardenal F, Fournel P, Harden S (2017) Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol 18:1116–1125

    Google Scholar 

  • Ferguson MK, Im HK, Watson S, Johnson E, Wigfield CH, Vigneswaran WT (2014) Association of body mass index and outcomes after major lung resection. Eur J Cardiothorac Surg 45:e94–e99

    Google Scholar 

  • Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM, Deming RL, Kozelsky TF, Marks RS, Jett JR, Adjei AA (2009) Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer 115:2721–2731. https://doi.org/10.1002/CNCR.24314

    Article  Google Scholar 

  • Friedlaender A, Liu SV, Passaro A, Metro G, Banna G, Addeo A (2020) The role of performance status in small-cell lung cancer in the era of immune checkpoint inhibitors. Clin Lung Cancer 21:e539–e543. https://doi.org/10.1016/j.cllc.2020.04.006

    Article  Google Scholar 

  • Fujimoto D, Uehara K, Sato Y, Sakanoue I, Ito M, Teraoka S, Nagata K, Nakagawa A, Kosaka Y, Otsuka K (2017) Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. Sci Rep 7:11373

    Google Scholar 

  • Galvano A, Peri M, Guarini AA, Castiglia M, Grassadonia A, De Tursi M, Irtelli L, Rizzo S, Bertani A, Gristina V, Barraco N, Russo A, Natoli C, Bazan V (2020) Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score. Ther Adv Med Oncol 12. https://doi.org/10.1177/1758835920942378

  • Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair MJ, Powell SF (2018) Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med 378:2078–2092

    Google Scholar 

  • George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park K-S, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun S-M, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi C, Kim Y-H, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun O-T, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK (2015) Comprehensive genomic profiles of small cell lung cancer. Nature 524:47–53. https://doi.org/10.1038/nature14664

    Article  Google Scholar 

  • Goldman JW, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Ponce S, Verderame F, Havel L, Bondarenko I, Każarnowicz A, Losonczy G, Conev NV, Armstrong J, Byrne N, Thiyagarajah P, Jiang H, Paz-Ares L, Dvorkin M, Trukhin D, Statsenko G, Voitko N, Poltoratskiy A, Bondarenko I, Chen Y, Kazarnowicz A, Paz-Ares L, Özgüroglu M, Conev N, Hochmair M, Burghuber O, Havel L, Çiçin I, Losonczy G, Moiseenko V, Erman M, Kowalski D, Wojtukiewicz M, Adamchuk H, Vasilyev A, Shevnia S, Valev S, Reinmuth N, Ji JH, Insa Molla MA, Ursol G, Chiang A, Hartl S, Horváth Z, Pajkos G, Verderame F, Hotta K, Kim S-W, Smolin A, Göksel T, Dakhil S, Roubec J, Bogos K, Garassino MC, Cornelissen R, Lee J-S, Garcia Campelo MR, Lopez Brea M, Alacacioglu A, Casarini I, Ilieva R, Tonev I, Somfay A, Bar J, Zer Kuch A, Minelli M, Bartolucci R, Roila F, Saito H, Azuma K, Lee G-W, Luft A, Urda M, Delgado Mingorance JI, Majem Tarruella M, Spigel D, Koynov K, Zemanova M, Panse J, Schulz C, Pápai Székely Z, Sárosi V, Delmonte A, Bettini AC, Nishio M, Okamoto I, Hendriks L, Mandziuk S, Lee YG, Vladimirova L, Isla Casado D, Domine Gomez M, Navarro Mendivil A, Morán Bueno T, Wu S-Y, Knoble J, Skrickova J, Venkova V, Hilgers W, Laack E, Bischoff H, Fülöp A, Laczó I, Kósa J, Telekes A, Yoshida T, Kanda S, Hida T, Hayashi H, Maeda T, Kawamura T, Nakahara Y, Claessens N, Lee KH, Chiu C-H, Lin S-H, Li C-T, Demirkazik A, Schaefer E, Nikolinakos P, Schneider J, Babu S, Lamprecht B, Studnicka M, Fausto Nino Gorini C, Kultan J, Kolek V, Souquet P-J, Moro-Sibilot D, Gottfried M, Smit E, Lee KH, Kasan P, Chovanec J, Goloborodko O, Kolesnik O, Ostapenko Y, Lakhanpal S, Haque B, Chua W, Stilwill J, Sena SN, Girotto GC, De Marchi PRM, Martinelli de Oliveira FA, Dos Reis P, Krasteva R, Zhao Y, Chen C, Koubkova L, Robinet G, Chouaid C, Grohe C, Alt J, Csánky E, Somogyiné Ezer É, Heching NI, Kim YH, Aatagi S, Kuyama S, Harada D, Nogami N, Nokihara H, Goto H, Staal van den Brekel A, Cho EK, Kim J-H, Ganea D, Ciuleanu T, Popova E, Sakaeva D, Stresko M, Demo P, Godal R, Wei Y-F, Chen Y-H, Hsia T-C, Lee K-Y, Chang H-C, Wang C-C, Dowlati A, Sumey C, Powell S, Goldman J, Zarba JJ, Batagelj E, Pastor AV, Zukin M, da Baldotto CSR, Schlittler LA, Calabrich A, Sette C, Dudov A, Zhou C, Lena H, Lang S, Pápai Z, Goto K, Umemura S, Kanazawa K, Hara Y, Shinoda M, Morise M, Hiltermann J, Mróz R, Ungureanu A, Andrasina I, Chang G-C, Vynnychenko I, Shparyk Y, Kryzhanivska A, Ross H, Mi K, Jamil R, Williamson M, Spahr J, Han Z, Wang M, Yang Z, Hu J, Li W, Zhao J, Feng J, Ma S, Zhou X, Liang Z, Hu Y, Chen Y, Bi M, Shu Y, Nan K, Zhou J, Zhang W, Ma R, Yang N, Lin Z, Wu G, Fang J, Zhang H, Wang K, Chen Z (2021) Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 22:51–65. https://doi.org/10.1016/S1470-2045(20)30539-8

    Article  Google Scholar 

  • Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WE, Nicholson AG, Groome P, Mitchell A, Bolejack V (2016) The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol 11:39–51

    Google Scholar 

  • Gong T, Liu J, Jiang J, Zhai Y-F, Wu C-M, Ma C, Wen B-L, Yan X-Y, Zhang X, Wang D-M (2019) The role of lactate deshydrogenase levels on non-small cell lung cancer prognosis: a meta-analysis. Cell Mol Biol 65:89–93

    Google Scholar 

  • Gu X-B, Tian T, Tian X-J, Zhang X-J (2015) Prognostic significance of neutrophil-to-lymphocyte ratio in non-small cell lung cancer: a meta-analysis. Sci Rep 5:1–9

    Google Scholar 

  • Haque W, Verma V, Polamraju P, Farach A, Butler EB, Teh BS (2018) Stereotactic body radiation therapy versus conventionally fractionated radiation therapy for early stage non-small cell lung cancer. Radiother Oncol 129:264–269

    Google Scholar 

  • Hellman S, Weichselbaum RR (1995) Oligometastases. J Clin Oncol 13:8–10. https://doi.org/10.1200/JCO.1995.13.1.8

    Article  Google Scholar 

  • Hirsch FR, Spreafico A, Novello S, Wood MD, Simms L, Papotti M (2008) The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol 3:1468–1481

    Google Scholar 

  • Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, Huemer F, Losonczy G, Johnson ML, Nishio M, Reck M, Mok T, Lam S, Shames DS, Liu J, Ding B, Lopez-Chavez A, Kabbinavar F, Lin W, Sandler A, Liu SV (2018) First-line Atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med 379:2220–2229. https://doi.org/10.1056/NEJMoa1809064

    Article  Google Scholar 

  • Huang Y, Wei S, Jiang N, Zhang L, Wang S, Cao X, Zhao Y, Wang P (2018) The prognostic impact of decreased pretreatment haemoglobin level on the survival of patients with lung cancer: a systematic review and meta-analysis. BMC Cancer 18:1–15

    Google Scholar 

  • Im H-J, Pak K, Cheon GJ, Kang KW, Kim S-J, Kim I-J, Chung J-K, Kim EE, Lee DS (2015) Prognostic value of volumetric parameters of 18 F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging 42:241–251

    Google Scholar 

  • Jin J, Yang L, Liu D, Li W (2020) Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis. BMJ Open 10:e035031

    Google Scholar 

  • Kaida H, Azuma K, Kawahara A, Sadashima E, Hattori S, Akiba J, Rominger A, Takamori S, Fujimoto K, Hosono M (2017) Prognostic impact of 18F-FDG PET parameters and molecular markers expression in resected non-small cell lung cancer patients. J Nucl Med 58:1047–1047

    Google Scholar 

  • Käsmann L, Niyazi M, Blanck O, Baues C, Baumann R, Dobiasch S, Eze C, Fleischmann D, Gauer T, Giordano FA (2018) Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer. Strahlenther Onkol 194:79–90

    Google Scholar 

  • Käsmann L, Taugner J, Eze C, Roengvoraphoj O, Dantes M, Gennen K, Karin M, Petrukhnov O, Tufman A, Belka C (2019) Performance status and its changes predict outcome for patients with inoperable stage III NSCLC undergoing multimodal treatment. Anticancer Res 39:5077–5081

    Google Scholar 

  • Käsmann L, Abdo R, Eze C, Dantes M, Taugner J, Gennen K, Roengvoraphoj O, Rades D, Belka C, Manapov F (2020) External validation of a survival score for limited-stage small cell lung cancer patients treated with chemoradiotherapy. Lung 198:201–206. https://doi.org/10.1007/s00408-019-00312-6

    Article  Google Scholar 

  • Kazandjian D, Gong Y, Keegan P, Pazdur R, Blumenthal GM (2019) Prognostic value of the lung immune prognostic index for patients treated for metastatic non–small cell lung cancer. JAMA Oncol 5:1481–1485

    Google Scholar 

  • Kim YT, Seong YW, Jung YJ, Jeon YK, Park IK, Kang CH, Kim JH (2013) The presence of mutations in epidermal growth factor receptor gene is not a prognostic factor for long-term outcome after surgical resection of non-small-cell lung cancer. J Thorac Oncol 8:171–178. https://doi.org/10.1097/JTO.0b013e318277a3bb

    Article  Google Scholar 

  • Lackey A, Donington JS (2013) Surgical management of lung cancer. Semin Intervent Radiol 30:133–140. https://doi.org/10.1055/s-0033-1342954

    Article  Google Scholar 

  • Leung CC, Lam TH, Yew WW, Chan WM, Law WS, Tam CM (2011) Lower lung cancer mortality in obesity. Int J Epidemiol 40:174–182

    Google Scholar 

  • Li J, Zhu H, Sun L, Xu W, Wang X (2019) Prognostic value of site-specific metastases in lung cancer: a population based study. J Cancer 10:3079–3086. https://doi.org/10.7150/jca.30463

    Article  Google Scholar 

  • Lim JH, Ryu J-S, Kim JH, Kim H-J, Lee D (2018) Gender as an independent prognostic factor in small-cell lung cancer: Inha lung cancer cohort study using propensity score matching. PLoS One 13:e0208492. https://doi.org/10.1371/journal.pone.0208492

    Article  Google Scholar 

  • Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K, Yin J, Zhan C, Wang Q (2019) Trends in the incidence, treatment, and survival of patients with lung cancer in the last four decades. Cancer Manage Res 11:943

    Google Scholar 

  • Maeda R, Yoshida J, Ishii G, Hishida T, Nishimura M, Nagai K (2011) Prognostic impact of histology on early-stage non-small cell lung cancer. Chest 140:135–145

    Google Scholar 

  • Martin-Ucar AE, Chaudhuri N, Edwards JG, Waller DA (2002) Can pneumonectomy for non-small cell lung cancer be avoided? An audit of parenchymal sparing lung surgery. Eur J Cardiothorac Surg 21:601–605. https://doi.org/10.1016/s1010-7940(02)00028-3

    Article  Google Scholar 

  • Mok TS, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, Castro G Jr, Srimuninnimit V, Laktionov KK, Bondarenko I (2019) Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet 393:1819–1830

    Google Scholar 

  • Nakamura H, Ando K, Shinmyo T, Morita K, Mochizuki A, Kurimoto N, Tatsunami S (2011) Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg 17:469–480

    Google Scholar 

  • Nattenmüller J, Wochner R, Muley T, Steins M, Hummler S, Teucher B, Wiskemann J, Kauczor H-U, Wielpütz MO, Heussel CP (2017) Prognostic impact of CT-quantified muscle and fat distribution before and after first-line-chemotherapy in lung cancer patients. PLoS One 12:e0169136

    Google Scholar 

  • Negre E, Coffy A, Langlais A, Daures J-P, Lavole A, Quoix E, Molinier O, Greillier L, Audigier-Valette C, Moro-Sibilot D (2020) Development and validation of a simplified prognostic score in SCLC. JTO Clin Res Rep 1:100016

    Google Scholar 

  • Nestle U, Schimek-Jasch T, Kremp S, Schaefer-Schuler A, Mix M, Küsters A, Tosch M, Hehr T, Eschmann SM, Bultel Y-P (2020) Imaging-based target volume reduction in chemoradiotherapy for locally advanced non-small-cell lung cancer (PET-Plan): a multicentre, open-label, randomised, controlled trial. Lancet Oncol 21(4):581–592

    Google Scholar 

  • Nicholson SA, Beasley MB, Brambilla E, Hasleton PS, Colby TV, Sheppard MN, Falk R, Travis WD (2002) Small cell lung carcinoma (SCLC): a clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 26(9):1184–1197

    Google Scholar 

  • Nicholson AG, Chansky K, Crowley J, Beyruti R, Kubota K, Turrisi A, Eberhardt WE, Van Meerbeeck J, Rami-Porta R, Goldstraw P (2016) The International Association for the Study of Lung Cancer Lung Cancer Staging Project: proposals for the revision of the clinical and pathologic staging of small cell lung cancer in the forthcoming eighth edition of the TNM classification for lung cancer. J Thorac Oncol 11:300–311

    Google Scholar 

  • Okada M, Nishio W, Sakamoto T, Uchino K, Yuki T, Nakagawa A, Tsubota N (2005) Effect of tumor size on prognosis in patients with non–small cell lung cancer: the role of segmentectomy as a type of lesser resection. J Thorac Cardiovasc Surg 129:87–93

    Google Scholar 

  • Pan M, Zhao Y, He J, Wu H, Pan Y, Yu Q, Zhou S (2021) Prognostic value of the Glasgow prognostic score on overall survival in patients with advanced non-small cell lung cancer. J Cancer 12:2395

    Google Scholar 

  • Pinson P, Joos G, Watripont P, Brusselle G, Pauwels R (1997) Serum neuron-specific enolase as a tumor marker in the diagnosis and follow-up of small-cell lung cancer. Respiration 64:102–107. https://doi.org/10.1159/000196651

    Article  Google Scholar 

  • Pinto JA, Vallejos CS, Raez LE, Mas LA, Ruiz R, Torres-Roman JS, Morante Z, Araujo JM, Gómez HL, Aguilar A (2018) Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? ESMO Open 3:e000344

    Google Scholar 

  • Pujol J-L, Quantin X, Jacot W, Boher J-M, Grenier J, Lamy P-J (2003) Neuroendocrine and cytokeratin serum markers as prognostic determinants of small cell lung cancer. Lung Cancer 39:131–138. https://doi.org/10.1016/s0169-5002(02)00513-5

    Article  Google Scholar 

  • Qin J, Lu H (2018) Combined small-cell lung carcinoma. Onco Targets Ther 11:3505–3511. https://doi.org/10.2147/OTT.S159057

    Article  Google Scholar 

  • Rades D, Douglas S, Veninga T, Schild SE (2012) A validated survival score for patients with metastatic spinal cord compression from non-small cell lung cancer. BMC Cancer 12:1–7

    Google Scholar 

  • Rades D, Dziggel L, Segedin B, Oblak I, Nagy V, Marita A, Schild S, Trang N, Khoa M (2013) A new survival score for patients with brain metastases from non-small cell lung cancer. Strahlenther Onkol 189:777–781

    Google Scholar 

  • Rades D, Hansen HC, Janssen S, Schild SE (2019) Comparison of diagnosis-specific survival scores for patients with small-cell lung cancer irradiated for brain metastases. Cancer 11:233

    Google Scholar 

  • Rothschild SI, Hagmann R, Zippelius A (2016) 92P: Validation of prognostic scores in small cell lung cancer. J Thorac Oncol 11:S96–S97. https://doi.org/10.1016/S1556-0864(16)30205-2

    Article  Google Scholar 

  • Sabari JK, Lok BH, Laird JH, Poirier JT, Rudin CM (2017) Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol 14:549–561. https://doi.org/10.1038/nrclinonc.2017.71

    Article  Google Scholar 

  • Saeed A, Salem ME (2020) Prognostic value of tumor mutation burden (TMB) and INDEL burden (IDB) in cancer: current view and clinical applications. Ann Transl Med 8:575. https://doi.org/10.21037/atm-2020-75

    Article  Google Scholar 

  • Schanne DH, Heitmann J, Guckenberger M, Andratschke NHJ (2019) Evolution of treatment strategies for oligometastatic NSCLC patients—a systematic review of the literature. Cancer Treat Rev 80. https://doi.org/10.1016/j.ctrv.2019.101892

  • Schild SE, Tan AD, Wampfler JA, Ross HJ, Yang P, Sloan JA (2015) A new scoring system for predicting survival in patients with non-small cell lung cancer. Cancer Med 4:1334–1343

    Google Scholar 

  • Scilla KA, Bentzen SM, Lam VK, Mohindra P, Nichols EM, Vyfhuis MA, Bhooshan N, Feigenberg SJ, Edelman MJ, Feliciano JL (2017) Neutrophil-Lymphocyte ratio is a prognostic marker in patients with locally advanced (Stage IIIA and IIIB) non-small cell lung cancer treated with combined modality therapy. Oncologist 22:737

    Google Scholar 

  • Shen X-B, Wang Y, Shan B-J, Lin L, Hao L, Liu Y, Wang W, Pan Y-Y (2019) Prognostic significance of platelet-to-lymphocyte ratio (PLR) and mean platelet volume (MPV) during etoposide-based first-line treatment in small cell lung cancer patients. Cancer Manag Res 11:8965–8975. https://doi.org/10.2147/CMAR.S215361

    Article  Google Scholar 

  • Shepshelovich D, Xu W, Lu L, Fares A, Yang P, Christiani D, Zhang J, Shiraishi K, Ryan BM, Chen C (2019) Body Mass Index (BMI), BMI change, and overall survival in patients with SCLC and NSCLC: a pooled analysis of the international lung cancer consortium. J Thorac Oncol 14:1594–1607

    Google Scholar 

  • Shibayama T, Ueoka H, Nishii K, Kiura K, Tabata M, Miyatake K, Kitajima T, Harada M (2001) Complementary roles of pro-gastrin-releasing peptide (ProGRP) and neuron specific enolase (NSE) in diagnosis and prognosis of small-cell lung cancer (SCLC). Lung Cancer (Amsterdam, Netherlands) 32:61–69. https://doi.org/10.1016/s0169-5002(00)00205-1

    Article  Google Scholar 

  • Simmons CP, Koinis F, Fallon MT, Fearon KC, Bowden J, Solheim TS, Gronberg BH, McMillan DC, Gioulbasanis I, Laird BJ (2015) Prognosis in advanced lung cancer—a prospective study examining key clinicopathological factors. Lung Cancer 88:304–309

    Google Scholar 

  • Smeltzer MP, Faris NR, Ray MA, Osarogiagbon RU (2018) Association of pathologic nodal staging quality with survival among patients with non–small cell lung cancer after resection with curative intent. JAMA Oncol 4:80–87

    Google Scholar 

  • Sonehara K, Tateishi K, Komatsu M, Yamamoto H, Hanaoka M (2020) Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer. Thorac Cancer 11:1578–1586. https://doi.org/10.1111/1759-7714.13432

    Article  Google Scholar 

  • Soo RA, Chen Z, Teng RSY, Tan H-L, Iacopetta B, Tai BC, Soong R (2018) Prognostic significance of immune cells in non-small cell lung cancer: meta-analysis. Oncotarget 9:24801

    Google Scholar 

  • Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. A Cancer J Clin, CA

    Google Scholar 

  • Tashima Y, Kuwata T, Yoneda K, Hirai A, Mori M, Kanayama M, Imanishi N, Kuroda K, Ichiki Y, Tanaka F (2020) Prognostic impact of PD-L1 expression in correlation with neutrophil-to-lymphocyte ratio in squamous cell carcinoma of the lung. Sci Rep 10:1–8

    Google Scholar 

  • Taugner J, Käsmann L, Eze C, Dantes M, Roengvoraphoj O, Gennen K, Karin M, Petruknov O, Tufman A, Belka C (2019) Survival score to characterize prognosis in inoperable stage III NSCLC after chemoradiotherapy. Transl Lung Cancer Res 8:593

    Google Scholar 

  • Tendler S, Grozman V, Lewensohn R, Tsakonas G, Viktorsson K, De Petris L (2018) Validation of the 8th TNM classification for small-cell lung cancer in a retrospective material from Sweden. Lung Cancer 120:75–81. https://doi.org/10.1016/j.lungcan.2018.03.026

    Article  Google Scholar 

  • Tian Z, Liang C, Zhang Z, Wen H, Feng H, Ma Q, Liu D, Qiang G (2020) Prognostic value of neuron-specific enolase for small cell lung cancer: a systematic review and meta-analysis. World J Surg Oncol 18:116. https://doi.org/10.1186/s12957-020-01894-9

    Article  Google Scholar 

  • Tjong MC, Mak DY, Shahi J, Li GJ, Chen H, Louie AV (2020) Current management and progress in radiotherapy for small cell lung cancer. Front Oncol 10:1146. https://doi.org/10.3389/fonc.2020.01146

    Article  Google Scholar 

  • Travis WD (2012) Update on small cell carcinoma and its differentiation from squamous cell carcinoma and other non-small cell carcinomas. Mod Pathol 25:S18–S30. https://doi.org/10.1038/modpathol.2011.150

    Article  Google Scholar 

  • Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340:265–271. https://doi.org/10.1056/NEJM199901283400403

    Article  Google Scholar 

  • Wagner A, Oertelt-Prigione S, Adjei A, Buclin T, Cristina V, Csajka C, Coukos G, Dafni U, Dotto G-P, Ducreux M (2019) Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol 30:1914–1924

    Google Scholar 

  • Wang B-Y, Huang J-Y, Chen H-C, Lin C-H, Lin S-H, Hung W-H, Cheng Y-F (2020) The comparison between adenocarcinoma and squamous cell carcinoma in lung cancer patients. J Cancer Res Clin Oncol 146:43–52

    Google Scholar 

  • Winther-Larsen A, Aggerholm-Pedersen N, Sandfeld-Paulsen B (2021) Inflammation scores as prognostic biomarkers in small cell lung cancer: a systematic review and meta-analysis. Syst Rev 10:40. https://doi.org/10.1186/s13643-021-01585-w

    Article  Google Scholar 

  • Yahya S, Ghafoor Q, Stevenson R, Watkins S, Allos B (2018) Evolution of stereotactic ablative radiotherapy in lung cancer and Birmingham’s (UK) experience. Medicines (Basel) 5:77

    Google Scholar 

  • Yokouchi H, Ishida T, Yamazaki S, Kikuchi H, Oizumi S, Uramoto H, Tanaka F, Harada M, Akie K, Sugaya F, Fujita Y, Fukuhara T, Takamura K, Kojima T, Harada T, Higuchi M, Matsuura Y, Honjo O, Minami Y, Watanabe N, Nishihara H, Suzuki H, Dosaka-Akita H, Isobe H, Nishimura M, Munakata M (2015) Prognostic impact of clinical variables on surgically resected small-cell lung cancer: results of a retrospective multicenter analysis (FIGHT002A and HOT1301A). Lung Cancer 90:548–553. https://doi.org/10.1016/j.lungcan.2015.10.010

    Article  Google Scholar 

  • Zhang J, Yao Y-H, Li B-G, Yang Q, Zhang P-Y, Wang H-T (2015a) Prognostic value of pretreatment serum lactate dehydrogenase level in patients with solid tumors: a systematic review and meta-analysis. Sci Rep 5:1–12

    Google Scholar 

  • Zhang Z, Han Y, Liang H, Wang L (2015b) Prognostic value of serum CYFRA 21-1 and CEA for non-small-cell lung cancer. Cancer Med 4:1633–1638

    Google Scholar 

  • Zhang L, Liu D, Li L, Pu D, Zhou P, Jing Y, Yu H, Wang Y, Zhu Y, He Y, Li Y, Zhao S, Qiu Z, Li W (2017a) The important role of circulating CYFRA21-1 in metastasis diagnosis and prognostic value compared with carcinoembryonic antigen and neuron-specific enolase in lung cancer patients. BMC Cancer 17:96. https://doi.org/10.1186/s12885-017-3070-6

    Article  Google Scholar 

  • Zhang M, Li G, Wang Y, Wang Y, Zhao S, Haihong P, Zhao H, Wang Y (2017b) PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep 7:10255. https://doi.org/10.1038/s41598-017-10925-7

    Article  Google Scholar 

  • Zhang Z, Li Y, Yan X, Song Q, Wang G, Hu Y, Jiao S, Wang J (2019) Pretreatment lactate dehydrogenase may predict outcome of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Cancer Med 8:1467–1473

    Google Scholar 

  • Zhang Y-H, Lu Y, Lu H, Zhou Y-M (2020) Development of a survival prognostic model for non-small cell lung cancer. Front Oncol 10:362

    Google Scholar 

  • Zhao X, Kallakury B, Chahine JJ, Hartmann D, Zhang Y, Chen Y, Zhang H, Zhang B, Wang C, Giaccone G (2019) Surgical resection of SCLC: prognostic factors and the tumor microenvironment. J Thorac Oncol 14:914–923. https://doi.org/10.1016/j.jtho.2019.01.019

    Article  Google Scholar 

  • Zheng M (2016) Classification and pathology of lung cancer. Surg Oncol Clin 25:447–468

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University Hospital, LMU Munich, Munich, Germany

    Lukas Käsmann

Authors
  1. Lukas Käsmann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lukas Käsmann .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Kragujevac, Kragujevac, Serbia

    Branislav Jeremić

Rights and permissions

Reprints and permissions

Copyright information

© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Käsmann, L. (2022). Importance of Prognostic Factors in Lung Cancer. In: Jeremić, B. (eds) Advances in Radiation Oncology in Lung Cancer. Medical Radiology(). Springer, Cham. https://doi.org/10.1007/174_2022_339

Download citation

  • DOI: https://doi.org/10.1007/174_2022_339

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-34846-4

  • Online ISBN: 978-3-031-34847-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation